High-Density Lipoprotein Metabolism in Human Apolipoprotein B\u3csub\u3e100\u3c/sub\u3e Transgenic/Brown Adipose Tissue Deficient Mice: A Model of Obesity-Induced Hyperinsulinemia by Ehlers, Sarah J. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Nutrition and Health Sciences -- Faculty
Publications Nutrition and Health Sciences, Department of
6-2011
High-Density Lipoprotein Metabolism in Human
Apolipoprotein B100 Transgenic/Brown Adipose
Tissue Deficient Mice: A Model of Obesity-
Induced Hyperinsulinemia
Sarah J. Ehlers
University of Nebraska-Lincoln
Stephanie M. Larson
University of Nebraska-Lincoln
Heather E. Rasmussen
University of Nebraska-Lincoln, heather.rasmussen@unl.edu
Young-Ki Park
University of Nebraska-Lincoln, young-ki.park@uconn.edu
Ji-Young Lee
University of Nebraska-Lincoln, ji-young.lee@uconn.edu
Follow this and additional works at: https://digitalcommons.unl.edu/nutritionfacpub
Part of the Human and Clinical Nutrition Commons, Molecular, Genetic, and Biochemical
Nutrition Commons, and the Other Nutrition Commons
This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Nutrition and Health Sciences -- Faculty Publications by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.
Ehlers, Sarah J.; Larson, Stephanie M.; Rasmussen, Heather E.; Park, Young-Ki; and Lee, Ji-Young, "High-Density Lipoprotein
Metabolism in Human Apolipoprotein B100 Transgenic/Brown Adipose Tissue Deficient Mice: A Model of Obesity-Induced
Hyperinsulinemia" (2011). Nutrition and Health Sciences -- Faculty Publications. 128.
https://digitalcommons.unl.edu/nutritionfacpub/128
 
 
 
Published in Applied Physiology, Nutrition, and Metabolism 36:3 (June 2011), pp. 313–322; 
doi: 10.1139/H11-003 
Copyright © 2011 Sarah J. Ehlers, Stephanie M. Larson, Heather E. Rasmussen, Young-Ki Park, and 
Ji-Young Lee; published by NRC Research Press. Used by permission. 
Submitted July 19, 2010; accepted December 23, 2010; published online May 16, 2011. 
 
 
High-Density Lipoprotein Metabolism in 
Human Apolipoprotein B100 Transgenic/Brown 
Adipose Tissue Deficient Mice: 
A Model of Obesity-Induced Hyperinsulinemia 
 
 
Sarah J. Ehlers, Stephanie M. Larson, Heather E. Rasmussen, 
Young-Ki Park, and Ji-Young Lee 
 
Department of Nutrition and Health Sciences, University of Nebraska–Lincoln, Lincoln, Nebraska, USA 
 
Corresponding author – J.-Y. Lee, email ji-young.lee@uconn.edu. Present address: Department of Nutritional Sciences, 
University of Connecticut, Storrs, CT 06269, USA. 
 
Abstract 
Obese and diabetic humans display decreased plasma high-density lipoprotein cholesterol (HDL-C) 
concentrations and an increased risk for coronary heart disease. However, investigation on HDL 
metabolism in obesity with a particular emphasis on hepatic ATP-binding cassette transporter A1 
(ABCA1), the primary factor for HDL formation, has not been well studied. Human apolipoprotein 
B100 transgenic (hApoBtg) and brown adipose tissue deficient (BATless) mice were crossed to generate 
hApoBtg/BATless mice. Male and female hApoBtg and hApoBtg/BATless mice were maintained on either 
a regular rodent chow diet or a diet high in fat and cholesterol until 24 weeks of age. The 
hApoBtg/BATless mice that were fed a HF/HC diet became obese, developed hepatic steatosis, and 
had significantly elevated plasma insulin levels compared with their hApoBtg counterparts, but 
plasma concentrations of total cholesterol, HDL-C, triglycerides, and free fatty acids and lipoprotein 
distribution between genotypes were not significantly different. Hepatic expression of genes encoding 
HDL-modifying factors (e.g., scavenger receptor, class B, type I, hepatic lipase, lecithin:cholesterol 
acyltransferase, and phospholipid transfer protein) was either altered significantly or showed a trend 
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of difference between 2 genotypes of mice. Importantly, hepatic protein levels of ABCA1 were sig-
nificantly lowered by ∼35% in male obese hApoBtg/BATless mice with no difference in mRNA levels 
compared with hApoBtg counterparts. Despite reduced hepatic ABCA1 protein levels, plasma HDL-C 
concentrations were not altered in male obese hApoBtg/BATless mice. The result suggests that hepatic 
ABCA1 may not be a primary contributing factor for perturbations in HDL metabolism in obesity-
induced hyperinsulinemia. 
 
Keywords: high density lipoprotein cholesterol, ATP-binding cassette transporter A-I, hApoBtg/BATless 
mice, insulin resistance, obesity 
 
Introduction 
 
Coronary heart disease (CHD) is one of the major metabolic diseases highly associated 
with the development of obesity, and it is strongly influenced by lifestyle and diet (De 
Lorgeril 2007). Atherosclerosis, a major underlying condition for CHD, is characterized by 
the buildup of atherosclerotic plaque in the arteries. This process may progress without 
any clinical symptoms but may manifest into a heart attack or stroke as plaque growth 
restricts blood flow. In humans, approximately 20% of circulating cholesterol is normally 
transported in high-density lipoprotein (HDL) (Attie 2007). Plasma HDL cholesterol (HDL-C) 
concentrations have an inverse relationship with the risk of CHD (Sasahara et al. 1997; Ooi 
et al. 2005; Van Gaal et al. 2006). Reduced plasma HDL-C concentrations by ∼15%–30% 
compared with normal subjects are associated with obesity and obesity-related disorders 
such as insulin resistance, metabolic syndrome, and type 2 diabetes (Gordon et al. 1977, 
1989; Krauss 2004; Ooi et al. 2005; Perségol et al. 2007), which may contribute in 1 way to 
the increased risk for CHD in the obese and diabetic population. 
The major athero-protective mechanism of HDL is reverse cholesterol transport (RCT), 
in which cholesterol is removed from peripheral tissues and carried to the liver for ultimate 
excretion from the body (Sasahara et al. 1998; Lee and Parks 2005; Lee et al. 2005). For this 
process, nascent HDL is necessary to take up excess cholesterol from the extrahepatic tis-
sues. Nascent HDL formation begins as a discoidal structure known as nascent or pre-β 
HDL, consisting of the major protein constituent apolipoprotein A-I (apoA-I), phospholip-
ids, and free cholesterol (Ooi et al. 2005; Singaraja et al. 2006), consequent to the interaction 
of apoA-I and ATP-binding cassette transporter A-1 (ABCA1). ABCA1 mediates the efflux 
of cellular phospholipids and free cholesterol to extracellular acceptors, namely lipid-free 
or lipid-poor apoA-I, producing pre-β HDL particles (Francis et al. 1995; Rogler et al. 1995; 
Brewer et al. 2004; Lee and Parks 2005; Lee et al. 2005). The significant role of ABCA1 in 
HDL formation is underscored by the finding that mutations in Abca1 lead to near absence 
of plasma HDL-C concentrations in patients with Tangier disease (Oram 2000) and Abca1 
knockout mice (Schreyer et al. 1994; McNeish et al. 2000; Francone et al. 2003). Interaction 
of apoA-I with ABCA1 produces heterogeneous-sized, pre-β migrating nascent HDL sub-
populations (pre-β1 to pre-β4) that vary in size, lipid, and apoA-I content in vitro and have 
different metabolic fates with less lipidated pre-β HDL being rapidly removed from the 
circulation without participating in RCT (Mulya et al. 2007, 2008). The nascent HDL 
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undergo maturation to become spherical mature particles by several plasma enzymes, in-
cluding lecithin:cholesterol acyltransferase (LCAT) (Brewer et al. 2004) and phospholipid 
transfer protein (PLTP) (Huuskonen et al. 2001). Mature HDL deliver the cholesterol 
mainly to the liver and steroidogenic tissues such as the adrenal glands, testis, and ovaries 
by interacting with the surface HDL receptor, scavenger receptor class B type I (SR-BI) 
(Acton et al. 1996; Krieger 1998, 1999). Hepatic lipase (HL) is another important enzyme 
whose action affects the rate of apoA-I catabolism by primarily hydrolyzing triglycerides 
in HDL particles. HL activity is increased when HDL particles are triglyceride-rich (Lewis 
and Rader 2005). 
Although reduced plasma HDL-C concentrations have been recognized in obese indi-
viduals, mechanisms underlying this phenomenon are not clearly understood. High plasma 
triglyceride levels and triglyceride enrichment in HDL particles have been suggested as a 
major reason for apoA-I and HDL hypercatabolism due to enhanced lipolysis by lipases, 
lowering plasma HDL-C levels in individuals with obesity and type 2 diabetes (Biesbroeck 
et al. 1982; Schaefer et al. 1982; Briones et al. 1984; Le and Ginsberg 1988; Frénais et al. 
1997). However, the apoA-I fractional catabolic rate (FCR) did not differ in the individuals 
with low HDL-C regardless of their plasma triglyceride concentration, supporting the 
presence of alternative mechanisms (Brinton et al. 1991). As mentioned, ABCA1 plays a 
pivotal role in nascent HDL formation. Importantly, deletion of Abca1 in the liver and in-
testine reduced plasma HDL-C concentrations by ∼80% and ∼30% in mice, respectively, 
indicating that ABCA1 in these tissues is quantitatively most important for maintaining 
plasma HDL-C levels (Timmins et al. 2005; Brunham et al. 2006). In addition to its role in 
nascent HDL formation, hepatic ABCA1 has been implicated in HDL catabolism. When 
125I-radiolabeled mature HDL particles were injected into mice, plasma die-away of the 
radiolabel was faster in mice with liver-specific deletion of Abca1 compared with wild-type 
counterparts (Timmins et al. 2005). Whether low plasma HDL-C concentrations in obese 
and diabetic subjects are attributed to any alterations in hepatic ABCA1 expression is not 
known. In this study, we intended to examine if the factors important in HDL formation, 
maturation, and catabolism are altered in obese mice compared with lean control animals. 
We chose brown adipose tissue (BAT) deficient (BATless) mice crossed with human 
apoB100 transgenic mice (hApoBtg) to generate hApoBtg/BATless mice. The hApoBtg/BATless 
mice on a high-fat–high-cholesterol diet showed dyslipidemia similar to that of humans 
with development of obesity and insulin resistance (Siri et al. 2001). 
 
Materials and methods 
 
Animal care and diet 
hApoBtg mice with low-density lipoprotein receptor knockout (hApoBtgldlr–/–) were obtained 
from Dr. Larry Rudel at Wake Forest University School of Medicine (Winston-Salem, North 
Carolina, USA) (Callow et al. 1994). To restore the expression of low-density lipoprotein 
receptor in hApoBtg mice, they were crossed with C57BL/6J mice and hApoBtgldlr+/+ mice 
were selected (hApoBtgldlr+/+ mice are referred to as hApoBtg hereafter). BATless mice were 
purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). The BATless mice were 
generated using the promoter of a BAT-specific uncoupling protein-1 (UCP-1) to drive the 
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expression of diphtheria toxin A, resulting in the loss of brown adipose tissue and weight 
gain (Lowell et al. 1993). Breeding pairs were set up with a hApoBtg and a BATless mouse, 
producing an hApoBtg control and hApoBtg/BATless mice. At 21 days of age, mice were 
weaned and tail biopsy (∼3–5 mm) was performed for DNA extraction and genotyping. 
Each DNA sample was tested for presence of the human apoB100 transgene as well as the 
wild-type and the BATless toxigene alleles by DNA amplification using the ExTaq Poly-
merase system (TaKaRa, Otsu, Shiga, Japan), after which they were subjected to 1% aga-
rose gel electrophoresis at 100 V for 70 min. Gels were visualized using Chemidoc XRS 
(Bio-Rad, Hercules, California, USA) and QuantityOne Software (Bio-Rad) with 2-log DNA 
ladder (New England BioLabs, Ipswich, Massachusetts, USA) for size identification. PCR 
primers used to identify human apoB100 were reported by Callow et al. (1994), and those 
for wild-type allele and BATless toxigen were provided by the Jackson laboratory. The 
primer sequences are listed in Table 1. 
 
Table 1. Primers for PCR genotyping and qPCR analysis 
Target Forward Reverse 
hApoBtg 5′-AGAAGGTTCCAGATGTCTATGAGG-3′ 5′-TCCAAGTATCTGTCTTCAAGAAACC-3′ 
Wild-type allele 5′-CAAATGTTGCTTGTCTGTG-3′ 5′-GTCAGTCGAGTGCACAGTTT-3′ 
BATless toxigene allele 5′-GCGCTGATGATGTTGTTGAT-3′ 5′-CATCCCCGAACCTTTTGATA-3′ 
GAPDH 5′-TGTGTCCGTCGTGGATCTGA-3′ 5′-CCTGCTTCACCACCTTCTTGAT-3′ 
apoA-I 5′-GACAGCGGCAGAGACTATGTGT-3′ 5′-CAGCTGTTGGCCCAAGGA-3′ 
SR-BI 5′-GATGTGGGCACCCTTCATG-3′ 5′-CCGGGCTGAAGAATTCCA-3′ 
LCAT 5′-GCTGGCCTGGTAGAGGAGATG-3′ 5′-GGCAGGATCACTGGTCTGGAT-3′ 
PLTP 5′-TGGGACGGTGTTGCTCAA-3′ 5′-CCCACGAGATCATCCACAGA-3′ 
HL 5′-GGCAGGATCACTGGTCTGGAT-3′ 5′-TGTTGATGTCCACCCCTTCA-3′ 
ABCA1 5′-CGTTTCCGGGAAGTGTCCTA-3′ 5′-GCTAGAGATGACAAGGAGGATGGA-3′ 
 
At weaning, mice were fed a Western-style diet that was high in fat and cholesterol (HF–
HC) (no. TD.88137 Adjusted Calories Diet; Harlan Teklad, Madison, Wisconsin, USA), con-
taining 17.3% protein, 48.5% carbohydrate, and 21.1% milk fat by weight and 4.5 kcal·g–1 
(1 kcal = 4.186 kJ). The HF–HC diet also contained 0.2% cholesterol by weight. Body 
weights were recorded at 4, 8, 12, 16, 20, and 24 weeks of age, and mice were sacrificed at 
24 weeks of age after an injection of a mixture of ketamine (50 mg·kg–1, Ketaject; Phoenix 
Pharmaceuticals, St. Joseph, Missouri, USA) and xylazine (10 mg·kg–1, Xyla-Ject; Phoenix 
Pharmaceuticals). Terminal blood was collected via cardiac puncture into a 2 mL EDTA-
coated BD Vacutainers (BD, Franklin Lakes, New Jersey, USA) and centrifuged at 5000g 
for 20 min at 4°C to remove red blood cells. Liver samples were quick frozen in liquid 
nitrogen and stored at –80°C until time of analysis. All animal procedures were approved by 
the Institutional Animal Care and Use Committee at the University of Nebraska–Lincoln. 
 
Plasma and liver lipid measurements 
Plasma concentrations and liver contents of total cholesterol (Roche Diagnostics, Indian-
apolis, Indiana, USA), triglycerides (Roche Diagnostics), and free cholesterol (Free Choles-
terol E, Wako Chemicals, Richmond, Virginia, USA) were determined by enzymatic 
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analysis as previously described (Rasmussen et al. 2009). HDL-C levels were measured 
using 10 μL plasma in 10 μL HDL-Precipitating Reagent (Thermo, Melbourne, Australia) 
according to the manufacturer’s instruction. Plasma levels of free fatty acids were meas-
ured using the NEFA-HR(2) kit (Wako, Richmond, Virginia, USA) as described in the man-
ufacturer’s protocol. 
Fast performance liquid chromatography (FPLC) analysis using 2 Superose 6 columns 
in series at a flow rate of 0.5 mL·min–1 was used to monitor lipoprotein distribution. Plasma 
from 4 mice of each HF–HC experimental group was pooled for a total of 200 μL for anal-
ysis and 100 fractions were collected and 50 μL of each fraction was used for total choles-
terol and triglyceride concentrations with enzymatic analysis as described above. 
 
Plasma insulin levels 
Plasma levels of insulin were measured by enzyme immunoassay using the Insulin 
(Mouse) Ultrasensitive EIA kit (Alpco Diagnostics, Salem, New Hampshire, USA) and fol-
lowing instructions for 5 μL of standard and sample. The optical density of the plate was 
measured at 450 nm with a reference wavelength of 620 nm. Data were presented as 
plasma concentration at ng · mL–1. 
 
Plasma LCAT and PLTP activities 
LCAT enzyme activity was measured according to the manufacturer’s protocol for the 
LCAT Activity Assay Kit, Fluorometric (Calbiochem, San Diego, California, USA). Fluo-
rescence intensity of each sample was measured with an FLx800 fluorometer (BioTek, Wo-
burn, Massachusetts, USA), using Gen5 software (BioTek) at an excitation of 340 nm and 
emissions of both 390 nm and 470 nm. The emission intensity at 390 nm represents the 
fluorescent emission of the hydrolyzed LCAT substrate while emission intensity at 470 nm 
represents the fluorescent emission of the nonhydrolyzed LCAT substrate. Data were re-
ported as a ratio of the 2 emission intensities (390/470). PLTP enzyme activity was meas-
ured using the PLTP Activity Assay Kit (BioVision, Mountain View, California, USA) 
according to the manufacturer’s protocol. Fluorescence intensity of each sample was meas-
ured with an FLx800 fluorometer using Gen5 software with an excitation of 465 nm and 
emission of 535 nm. 
 
Quantitative realtime PCR (qPCR) and Western blot analysis 
Total RNA was isolated from liver samples using TRIzol reagent (Invitrogen, Carlsbad, 
California, USA) and qPCR analysis was performed as previously described (Rasmussen 
et al. 2009). Primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), ABCA1, 
LCAT, PLTP, HL, apoA-1, and SRB1 were designed according to GenBank database using 
the Primer Express software provided by ABI and are listed in Table 1. 
Protein was isolated from liver samples using radioimmune precipitation (RIPA) buffer 
(50 mmol · L–1 Tris-HCl at pH 7.4, 150 mmol · L–1 NaCl, 0.25% sodium deoxycholate, 1% 
Nonidet P-40, 1 mmol · L–1 EDTA) containing Protease Inhibitor Cocktail III (Calbiochem, 
San Diego, California, USA) and used for Western blot analysis as described before (Park 
et al. 2008; Rasmussen et al. 2008). Rabbit antimouse ABCA1 antibody was provided as a 
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courtesy from Dr. John Parks at Wake Forest University School of Medicine (Winston-Salem, 
North Carolina, USA). β-Actin was used as a loading control to normalize the data. 
 
Statistical analysis 
One-way analysis of variance (ANOVA) and Tukey’s pairwise comparison or unpaired t 
test was used to identify significant differences between genotypes of each gender. p values 
of < 0.05 were considered significant by GraphPad InStat 3 (GraphPad Software, Inc., San 
Diego, California, USA). Data are expressed as means ± SD. 
 
Results 
 
General observations 
Body weights of mice on a chow or an HF–HC diet were recorded at 4, 8, 12, 16, 20, and 24 
weeks of age. There was no statistically significant difference in body weight between 
hApoBtg and hApoBtg/BATless mice on a chow diet through 24 weeks irrespective of gender 
(33.4 ± 1.7 g vs. 32.7 ± 2.4 g for male; 25.1 ± 0.76 g vs. 24.2 ± 0.56 g for female). However, in 
mice fed an HF–HC diet, the body weights of hApoBtg/BATless mice were significantly 
higher than control hApoBtg mice starting at 8 weeks and continuing through the end of the 
study for both male and female animals (Fig. 1). For male and female mice, body weights 
of hApoBtg/BATless mice were ∼25% and ∼38% over ApoBtg control mice, respectively, con-
firming that hApoBtg/BATless mice developed diet-induced obesity. 
 
 
 
Figure 1. Body weight change of male and female hApoBtg and hApoBtg/BATless mice fed 
an HF–HC diet over the course of the 24-week study. Values represent means ± SD. Data 
were analyzed using 1-way ANOVA and Tukey’s pairwise comparison at each week. 
Means at the same weeks of age having different superscripts are significantly different 
(p < 0.05). Male hApoBtg, n = 12; male hApoBtg/BATless, n = 11; female hApoBtg, n = 11; female 
hApoBtg/BATless, n = 7. 
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Plasma lipids and insulin 
Plasma total cholesterol, triglyceride, and free fatty acid concentrations were not signifi-
cantly different between hApoBtg control and hApoBtg/BATless obese mice on an HF–HC diet 
in both genders (Table 2). Plasma samples from male mice of each genotype were subjected 
to fractionation by using 2 Superose 6 columns to monitor lipoprotein distribution. Peaks 
corresponding with very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), 
and HDL were identified based upon total cholesterol as well as triglyceride concentra-
tions of each fraction and labeled as such with the VLDL peak centered at fraction 35, the 
LDL peak at fraction 50, and the HDL peak at fraction 65 (Fig. 2). As expected based on no 
significant difference in plasma total cholesterol concentrations, lipoprotein distribution 
was similar between the 2 genotypes of mice with a minor increase in cholesterol in the 
LDL fraction in hApoBtg/BATless mice. Triglyceride in VLDL and LDL fraction showed a 
moderate increase in hApoBtg/BATless mice compared with hApoBtg mice but there was no 
significant difference in plasma triglyceride concentrations between 2 genotypes of mice. 
Additionally, triglyceride enrichment in HDL fraction was not observed with hApoBtg/ 
BATless mice. 
 
Table 2. Plasma chemistry of hApoBtg and hApoBtg/BATless mice fed a high-fat–high-cholesterol diet until 24 weeks of age 
 Gender n 
TC 
(mg·dL–1) 
HDL-C 
(mg·dL–1) 
TG 
(mg·dL–1) 
FFA 
(mEq·L–1) 
Insulin 
(ng·mL–1) 
LCAT activity 
(OD390/OD470) 
PLTP activity 
(fluorescence) 
hApoBtg Male 12 391±114 110±26 156±63 0.32±0.08 0.5±0.2 2.2±0.3 9947±992 
hApoBtg/BATless Male 11 494±171 122±33 205±100 0.30±0.11 5.6±3.7* 2.3±0.4 10901±1196* 
hApoBtg Female 11 328±99 93±27 122±42 0.38±0.14 0.4±0.1 2.2±0.6 8043±1117 
hApoBtg/BATless Female   7 322±73 66±30 155±36 0.35±0.23 1.6±1.9* 2.0±0.3 8016±1797 
Note: Values represent means ± SD. TC, total cholesterol; HDL-C, HDL cholesterol; TG, triglyceride; FFA, free fatty acids; LCAT, 
lecithin:cholesterol acyltransferase; PLTP, phospholipid transfer protein. 
*Significantly different from hApoBtg within the same gender (p < 0.05). 
 
Fasting plasma insulin levels of hApoBtg/BATless obese mice were several-fold higher 
than hApoBtg control mice for both genders of animals (Table 2). Body weight of mice was 
significantly correlated with fasting insulin levels (r = 0.54, p = 0.0003), suggesting fasting 
plasma insulin increases with body weight in these mice. 
As important factors for HDL maturation and remodeling, plasma LCAT and PLTP ac-
tivities were measured. Plasma LCAT activity did not significantly differ between geno-
types of each gender, but plasma PLTP activity was significantly higher only in male 
hApoBtg/BATless obese mice compared with male control mice (Table 2). 
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Figure 2. Plasma lipoprotein distribution by fast performance liquid chromatography 
(FPLC) analysis. Pooled plasma samples (200 μL) from 4 male mice of each genotype fed a 
high-fat–high-cholesterol diet were fractionated by 2 Superpose 6 columns in series at a 
flow rate of 0.5 · mL·min–1. Each fraction (50 μL) was enzymatically analyzed for total cho-
lesterol and triglyceride and peaks for very-low-density lipoprotein (VLDL), low-density 
lipoprotein (LDL), and high-density lipoprotein (HDL) were identified. A representative 
FPLC profile from 2 separate analyses is shown. 
 
Liver lipids and gene analysis 
Obesity-induced insulin resistance is commonly linked with steatosis in the liver. Liver 
weights of male and female hApoBtg/BATless mice on an HF–HC diet were ∼2-fold more 
than those of hApoBtg control mice with significantly increased triglyceride, esterified cho-
lesterol, and free cholesterol content (Table 3). 
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Table 3. Liver lipid contents of hApoBtg and hApoBtg/BATless mice fed a high-fat–high-cholesterol 
diet until 24 weeks of age 
 Gender n 
Liver 
weight 
(G) 
TG 
(mg·g–1 
wet weight) 
FC 
(mg·g–1 
wet weight) 
EC 
(mg·g–1 
wet weight) 
PL 
(mg·g–1 
wet weight) 
hApoBtg Male 12 2.3±0.9 120±90 2.5±0.5 7.3±4.4 16.9±2.7 
hApoBtg/BATless Male 11 5.5±1.3* 272±60* 3.4±0.8* 20.0±5.0* 13.1±2.0* 
hApoBtg Female 11 1.7±0.6 90±46 2.4±0.2 9.5±1.8 17.9±1.8 
hApoBtg/BATless Female   7 3.4±0.9* 161±95* 2.6±0.3* 11.9±5.5 15.6±2.9* 
Note: Values represent means ± SD. hApoBtg, human apolipoprotein B100 transgenic; BATless, brown adipose 
tissue deficient; TG, triglyceride; FC, free cholesterol; EC, esterified cholesterol; PL, phospholipid. 
*Significantly different from hApoBtg within the same gender (p < 0.05). 
 
qPCR analysis was performed to measure mRNA abundance of lipogenic and HDL-
modulating genes in mice fed an HF–HC diet (Table 4). In male hApoBtg/BATless obese 
mice, a lipogenic gene stearoyl coA desaturease 1 (SCD-1) (p < 0.05) showed an increase, 
whereas acyl-CoA oxidase (AOX), an enzyme involving fatty acid oxidation in peroxi-
somes, was significantly lowered (p < 0.05). Fatty acid synthase (FAS) showed a trend to-
ward increase in the male hApoBtg/BATless obese mice (p = 0.08). Although we did not detect 
statistically significant differences, a similar trend was found for SCD-1 and AOX mRNA 
levels in the livers of female mice. Despite no differences in plasma LCAT activity, hepatic 
LCAT mRNA levels were significantly lower in hApoBtg/BATless mice than control mice in 
both genders. Expression of HL (p = 0.059) and SR-BI (p < 0.05) was lowered in 
hApoBtg/BATless male obese mice compared with control animals, and a similar trend was 
observed with female mice. A trend toward an increase was observed with PLTP mRNA 
levels in the livers of male (p = 0.085) and female (p = 0.058) hApoBtg/BATless mice. 
 
Table 4. Hepatic gene expression of hApoBtg and hApoBtg/BATless mice fed a high-fat–high-cholesterol 
diet at 24 weeks 
 Male  Female 
Enzyme hApoBtg hApoBtg/BATless  hApoBtg hApoBtg/BATless 
FAS 0.42±0.31 0.81±0.65  1.07±0.50 0.97±0.76 
AOX 1.25±0.36 0.89±0.41*  1.28±0.51 1.00±0.18 
LDLR 1.02±0.45 1.06±0.59  0.95±0.29 0.62±0.23* 
HMGR 1.25±0.53 1.29±1.05  0.74±0.25 0.71±0.42 
SCD-1 0.56±0.44 0.95±0.39*  0.71±0.48 1.12±0.48 
SREBP-1c 1.00±0.20 0.80±0.26  0.80±0.43 0.68±0.20 
SREBP-2 0.89±0.31 0.88±0.32  1.12±0.38 0.80±0.13 
ChREBP 0.89±0.31 0.47±0.27*  0.99±0.37 0.94±0.62 
LCAT 1.38±0.39 0.68±0.28*  1.04±0.56 0.47±0.13* 
PLTP 1.18±0.51 1.67±0.73  1.49±0.53 2.62±1.74 
HL 1.28±0.46 0.91±0.43  0.91±0.37 0.50±0.21* 
apoA-I 0.79±0.31 0.62±0.27  0.76±0.51 0.53±0.14 
SR-BI 0.99±0.52 0.56±0.30*  0.94±0.66 0.50±0.19 
Note: Values represent means ± SD. Means were analyzed using unpaired t test within the same gender. n = 7–12. 
*Significantly different from hApoBtg within the same gender (p < 0.05). 
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As hepatic ABCA1 is the primary factor for HDL formation, hepatic expression of 
ABCA1 was measured in mice. No significant difference was detected in the hepatic 
ABCA1 mRNA abundance between male hApoBtg and hApoBtg/BATless mice (Fig. 3). How-
ever, Western blot analysis showed that hepatic ABCA1 protein was significantly lower by 
∼35% in hApoBtg/BATless mice compared with hApoBtg mice. No significant differences in 
ABCA1 mRNA and protein levels were observed in both genotypes of female mice (data 
not shown). 
 
 
 
Figure 3. Hepatic mRNA and protein levels of ABCA1. Liver samples of male hApoBtg and 
hApoBtg/BATless mice fed an HF–HC diet were analyzed by qPCR for mRNA abundance 
(A) and by Western blot for protein levels (B). Data were analyzed using unpaired t test. 
Dots represent each animal and horizontal lines are for means. 
 
Discussion 
 
Obesity and obesity-associated metabolic diseases are currently prominent health prob-
lems in the United States and westernized countries. Among various complications of obe-
sity, accelerated CHD has emerged as a leading cause of morbidity and mortality with the 
incidence being 2- to 8-fold higher for the subjects with insulin resistance and type 2 dia-
betes (Grundy et al. 2002; Howard et al. 2002; Wendt et al. 2002). Mechanistic understand-
ing for this phenomenon, however, is very limited. We utilized hApoBtg/BATless mice on 
an HF–HC diet to investigate alterations in factors affecting HDL metabolism in obesity-
induced hyperinsulinemia. 
While humans carry the majority of their circulating cholesterol in LDL, mice carry the 
majority of their cholesterol in HDL (Salmon and Hems 1973). However, mice with human 
apoB100 transgene have cholesterol accumulation in the LDL fraction with similar lipopro-
tein distribution to that of humans (Linton et al. 1993). Common obesity or type 2 diabetes 
mouse models, such as ob/ob, db/db, fat/fat and tub/tub mice, exhibit elevated plasma HDL-C 
levels along with weight gain in contrast to obese humans (Nishina et al. 1994). BATless 
mice generated using a BAT-specific UCP-1 promoter to drive the expression of diphtheria 
toxin A become obese on a high-fat diet consequent to loss of BAT (Lowell et al. 1993). To 
generate a mouse model of obesity-induced dyslipidemia, hApoBtg mice were crossed with 
BATless mice. The resulting hApoBtg/BATless mice on an HF–HC diet have previously been 
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shown to be susceptible to diet-induced obesity, hypercholesterolemia, hypertriglycer-
idemia, and hyperinsulinemia (Siri et al. 2001). In addition, the plasma lipid profile of male 
hApoBtg/BATless mice on an HF–HC diet has been shown to be similar to that of obese and 
diabetic humans in regards to lipoprotein distribution and size with reduced plasma HDL-C 
levels compared with hApoBtg control mice (Siri et al. 2001). Our initial intention was to 
utilize this mouse model of obesity-induced insulin resistance and dyslipidemia for eluci-
dation of altered HDL metabolism. Male hApoBtg/BATless mice on an HF–HC diet indeed 
developed hyperinsulinemia with weight gain compared with control mice. However, in-
consistent with the previous report by Siri et al. (2001) that plasma HDL-C levels were 
reduced in male hApoBtg/BATless mice, we did not observe the reduction in our mice. The 
reason for this discrepancy is not known. However, we speculate that it may be related to 
difference in the genetic background of the mice. hApoBtg mice used in the study of Siri et 
al. (2001) had C57BL/6J background whereas ours had a mixed background. An additional 
noticeable difference between these 2 studies is plasma triglyceride concentrations. Com-
pared with male hApoBtg control mice, plasma triglyceride levels were significantly in-
creased in the study by Siri et al. (2001) but there was no significance difference in our mice 
(p = 0.18). It is possible that because of the disparate genetic background of hApoBtg mice, 
apoB100-containing lipoprotein metabolism could differ between 2 studies. Particularly, it 
is noteworthy that a reduction in plasma HDL-C levels was observed only in the presence 
of significantly elevated plasma triglyceride levels in hApoBtg/BATless mice shown in Siri 
et al.’s study given an inverse relationship between plasma HDL-C and triglyceride con-
centrations. In the obese male hApoBtg/BATless mice, hepatic SR-BI mRNA levels were sig-
nificantly lowered. As SR-BI in the liver provides a major HDL particle clearance pathway, 
the reduction may contribute to absence of HDL-C lowering in our obese mice. However, 
as hepatic SR-BI expression was not measured in Siri et al.’s study, it remains speculative. 
Absence of functional ABCA1 reduced plasma HDL-C concentrations by ∼95% in hu-
mans and mice (Oram 2000; Brunham et al. 2006), suggesting ABCA1 is quantitatively the 
most important factor in maintaining plasma HDL-C levels. In particular, as ABCA1 in the 
liver accounts for ∼80% of plasma HDL-C levels (Timmins et al. 2005), hepatic expression 
of ABCA1 was evaluated to gain an insight into a potential contribution of hepatic ABCA1 
to the HDL metabolism in obesity. There was no significant difference in hepatic ABCA1 
mRNA transcript levels between male hApoBtg control and hApoBtg/BATless obese mice. 
However, ABCA1 protein levels in the livers of male hApoBtg/BATless mice were signifi-
cantly reduced by ∼35% compared with those of hApoBtg control mice. This is the first 
study, to our knowledge, to demonstrate a post-transcriptional repression of hepatic ABCA1 
expression in vivo in obesity-induced insulin resistance. Studies have shown that unsatu-
rated fatty acids lower ABCA1 protein levels in macrophages without altering mRNA lev-
els by facilitating ABCA1 protein degradation via the activation of phospholipase 
D2/protein kinase C δ pathway (Wang and Oram 2002, 2005, 2007). Therefore, it can be 
postulated that increased fat contents in the livers of hApoBtg/BATless obese mice could 
facilitate ABCA1 protein degradation. It should be noted that in spite of significant reduc-
tion in hepatic ABCA1 protein in hApoBtg/BATless mice by ∼35% compared with hApoBtg 
mice, plasma HDL-C concentrations were not different between 2 genotypes. Reduction in 
hepatic ABCA1 by ∼45%–50% either by heterozygous gene deletion (Lee et al. 2005) or 
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using small interfering RNA (Ragozin et al. 2005) resulted in ∼45%–50% decrease in 
plasma HDL-C concentrations. Absence of altered plasma HDL-C levels in our hApoBtg/ 
BATless mice even with ∼35% reduction in hepatic ABCA1 protein could indicate that the 
extent of reduction may not be enough to alter plasma HDL-C levels in a state of obesity-
induced insulin resistance. Alternatively, triglyceride enrichment in HDL particles, which 
was absent in our study, could be a primary factor to lower plasma HDL-C levels in obesity. 
Factors that could modulate HDL formation and catabolism, including apoA-I, SR-BI, 
HL, LCAT, and PLTP, were investigated for their participation in HDL metabolism in obesity-
related insulin resistance. ApoA-I accounts for ∼70% of total proteins in HDL particles 
(Lewis and Rader 2005) and its absence in mice leads to extremely low levels of plasma 
HDL-C levels along with increased atherosclerosis (Lewis and Rader 2005; Moore et al. 
2005). Hepatic SR-BI mediates the selective uptake of cholesteryl ester from the HDL par-
ticles and thus increased expression of SR-BI in mice increases HDL uptake into the liver, 
lowering plasma HDL-C levels (Kozarsky et al. 1997). HL may affect rates of apoA-I catab-
olism in HDL by increasing the hydrolysis of HDL triglycerides (Rader 2006). Two plasma 
enzymes, LCAT and PLTP, are responsible for maturation of HDL particles. The formation 
of cholesteryl esters in the core of HDL particles from free cholesterol on the lipoprotein 
surface is mediated by LCAT (Rader 2006). Decreased LCAT has been shown to increase 
catabolism of apoA-I and apoA-II, resulting in lower plasma levels of HDL-C (Rader et al. 
1994). As a mediator of phospholipid transfer from apoB-containing lipoproteins to HDL 
particles, increased PLTP is associated with increased plasma HDL-C levels, whereas re-
duced PLTP leads to decreased plasma HDL-C concentrations (Jiang et al. 1996, 1999). In 
our study, we observed that the hepatic expression of HDL-modulating receptor and en-
zymes, such as SR-BI, HL, LCAT and PLTP, was either significantly altered or showed at 
least a trend of difference between hApoBtg control and hApoBtg/BATless obese mice. How-
ever, plasma HDL-C levels were not significantly different between 2 genotypes of mice. 
It would be possible that their protein levels and (or) activity might not be altered as shown 
in plasma LCAT activity. It can be alternatively postulated that the factors minimally con-
tribute to plasma HDL-C levels in hApoBtg/BATless obese mice. 
Etiology for perturbed HDL metabolism in obesity and obesity-related abnormal meta-
bolic conditions is not clear. In obesity-induced hyperinsulinemia, altered expression of 
HDL-modulating factors, hepatic ABCA1 in particular, was not able to lower plasma HDL-C 
concentrations in our study. Plasma HDL-C levels were lowered concomitantly with ele-
vated plasma triglycerides in hApoBtg/BATless obese mice (Siri et al. 2001). However, we 
observed that the mice did not exhibit a reduction in plasma HDL-C when plasma triglyc-
eride levels remained unaltered. It is likely that triglyceride enrichment in HDL particles 
and resulting hypercatabolism of the particles could be a major contributor to perturbed 
HDL metabolism in obesity and obesity-related hyperinsulinemia. Fat overflow in obesity 
potentially outweighs the effects of other HDL modifying factors that otherwise have a 
large impact on HDL metabolism. 
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